AlphaMark Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

AlphaMark Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$13K	Hold	369	–	–	0.01%	411
2024 Q3	$15K	Sell	369 -201	-35%	-$9.35K	0.01%	466
2024 Q2	$27K	Buy	570 +170	+43%	+$6.97K	0.01%	411
2024 Q1	$17K	Sell	400 -100	-20%	-$4.77K	0.01%	462
2023 Q4	$25K	Hold	500	–	–	0.01%	424
2023 Q3	$23K	Hold	500	–	–	0.01%	414
2023 Q2	$21K	Hold	500	–	–	0.01%	308
2023 Q1	$18K	Sell	500 -50	-9%	-$1.88K	0.01%	332
2022 Q4	$21K	Hold	550	–	–	0.01%	286
2022 Q3	$24K	Sell	550 -5	-0.9%	-$211	0.01%	291
2022 Q2	$21K	Hold	555	–	–	0.01%	309
2022 Q1	$21K	Buy	555 +375	+208%	+$12.3K	0.01%	323
2021 Q4	$5K	Sell	180 -15	-8%	-$472	﹤0.01%	452
2021 Q3	$7K	Sell	195 -5	-3%	-$188	﹤0.01%	436
2021 Q2	$8K	Buy	+200	New	+$7.83K	﹤0.01%	424
2017 Q3	–	Sell	-165	Closed	-$8K	–	518
2017 Q2	$8K	Hold	165	–	–	﹤0.01%	369
2017 Q1	$7K	Hold	165	–	–	﹤0.01%	366
2016 Q4	$8K	Buy	+165	New	+$6.53K	﹤0.01%	334

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

AlphaMark Advisors's IONS Position: Q4 2024 in Review

AlphaMark Advisors held its Ionis Pharmaceuticals (IONS) position steady in Q4 2024 at 369 shares worth $13K. The position accounts for 0.01% of the portfolio, ranked #411.

AlphaMark Advisors first reported a position in IONS in Q4 2016 and has held it in 18 quarters since. The position peaked at $27K in Q2 2024. 355 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

AlphaMark Advisors held 369 shares of Ionis Pharmaceuticals worth $13K as of Q4 2024.
AlphaMark Advisors left its Ionis Pharmaceuticals share count unchanged in Q4 2024.
Ionis Pharmaceuticals made up 0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #411 holding.
AlphaMark Advisors first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 18 quarters since.
AlphaMark Advisors's Ionis Pharmaceuticals position peaked at $27K in Q2 2024.
355 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.